Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka to Launch TS-1 in Europe in 2nd Quarter of 2012
September 5, 2011
- Takeda Begins M&A Talks with 2 Indian Companies: Local Paper
September 5, 2011
- Eisai’s, DSP’s Growth Scenario Becoming More Realistic: Tachibana Securities
September 5, 2011
- Takeda to Construct New Production Facilities for Flu Vaccines at Its Hikari Plant
September 5, 2011
- Kitasato Daiichi Sankyo Vaccine to Construct New-type Flu Vaccine Manufacturing Facilities
September 5, 2011
- KIX-Medica Increases Total Capacity
September 5, 2011
- BMKK Encourages Its MRs to Use Hybrid Cars
September 5, 2011
- Otsuka to Create Special Subsidiary for Employees with Disabilities
September 5, 2011
- Astellas Files for Mirabegron in US and Europe
September 5, 2011
- NDA for Lurasidone Accepted in Canada: DSP
September 5, 2011
- Large-scale Users Should Accept “Unit Price-based, By-product Deals”: Mr Bessho of JPWA
September 5, 2011
- Over 10% of Pharmacists Switched to Generic Actos in Just 1 Week: Nextit
September 5, 2011
- CSD Report Highlights Growing Importance of Biopharmaceutical Market in 2010
September 5, 2011
- Sanwa Kagaku Licenses Anagliptin to Kowa in China, Taiwan
September 5, 2011
- MSD Launches Gardasil for Prevention of Cervical Cancer
September 5, 2011
- Mediscience Chairman Urae Appoints President to Consolidate Management
September 2, 2011
- Daiichi Sankyo Espha Asks Patent Office to Invalidate Combination Patents for Takeda’s Actos
September 2, 2011
- Companies Responsible for Disclosure of Pharmacoeconomic Data: Chairman Eiki of Bayer Yakuhin
September 2, 2011
- Ontario Canada Supports Roche Canada’s New Research Site
September 2, 2011
- Sanofi Pasteur Appoints New GM
September 2, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…